EYLEA (aflibercept), anti-VEGF
OPHTHALMOLOGY - New indication
Opinions on drugs - Posted on Jan 26 2017
Reason for request
Extension of indication
Moderate clinical added value, as is the case with LUCENTIS, in visual impairment due to myopic choroidal neovascularisation
- EYLEA has Marketing Authorisation in adults, in the treatment of visual impairment due to myopic choroidal neovascularisation (CNV).
- A study has demonstrated a substantial improvement in visual acuity by comparison with sham intravitreal injections (+14.1 letters on the ETDRS scale).
- Despite the absence of comparative data versus ranibizumab, EYLEA may be considered a 1st line treatment just as LUCENTIS in this indication.
Clinical Added Value
Évaluation des médicaments